Related Experiment Video
Updated: Apr 14, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
β-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration
1Division of Cardiovascular Medicine, Endocrinology and Metabolism, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan.
Abstract:
Heart failure is currently a social welfare and economic burden. In particular, the prevalence of heart failure with preserved ejection fraction (HFpEF) has increased and is currently equal to that of heart failure with reduced ejection fraction (HFrEF). Prognosis of HFrEF has improved in the past two decades, because many clinical studies have revealed the effectiveness of several pharmacological and non-pharmacological interventions for HFrEF patients, one of which is β-blockers. In contrast, there is no established therapeutic intervention to provide beneficial effects on HFpEF, and mortality and morbidity of HFpEF are currently as poor as those of HFrEF. This review will discuss β-blockers from a standpoint of therapeutic strategy for HFpEF.
Related Concept Videos
Heart Failure Drugs: β-Blockers
Heart Failure V: Medical Management
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Heart Failure Drugs: Diuretics
